NRXPW NRX Pharmaceuticals, Inc.

Price Chart

Executive Summary

NRx Pharmaceuticals is conducting a firm-commitment underwritten public offering of 5,714,286 shares of common stock at $3.50 per share, raising approximately $18.8 million in net proceeds (or ~$21.6 million if the underwriters' over-allotment option is fully exercised). The offering price represents a ~24% discount to the last closing price of $4.62 on June 2, 2026. Proceeds are earmarked for working capital and general corporate purposes. The filing also discloses a negative tangible book value of $(0.49) per share as of March 31, 2026, with new investors facing immediate dilution of $3.44 per share.

Actionable Insight

Key Facts

• Offering of 5,714,286 shares of common stock at $3.50 per share (24% discount to $4.62 close on June 2, 2026)
• Net proceeds of ~$18.8 million (or ~$21.6 million if over-allotment fully exercised)
• Pro forma net tangible book value per share after offering: $0.06, vs. $(0.49) before offering
• Immediate dilution of $3.44 per share for new investors
• Underwriters: BTIG (lead) and Lucid Capital Markets
• Lock-up agreements: officers, directors, and company subject to 60-day lock-up
• Auditors' reports include going-concern explanatory paragraphs for FY2024 and FY2025
• Outstanding warrants: 9,359,710 shares at $7.77 weighted average exercise price

Financial Impact

~$18.8M net proceeds raised at a 24% discount to market, with $3.44/share dilution for new investors

Risk Factors

• Immediate 24% discount to market price creates arbitrage opportunity for new investors
• Going-concern qualification in audited financials indicates high cash burn risk
• Substantial warrant overhang (9.36M shares at $7.77) may pressure stock if exercised
• Management has broad discretion over use of proceeds with no specific allocation

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status

Related Tickers